China cut cancer-drug prices by covering the rich, not by targeting subsidies at the poor

Before 2016, China's universal health insurance excluded innovative drugs entirely, forcing patients needing cutting-edge treatments, including many cancer therapies, to pay the full retail price out of pocket. The standard policy instinct for making expensive drugs affordable on a constrained budget is to means-test coverage narrowly: subsidize only the patients who genuinely can't pay, so the government isn't 'wasting' money covering wealthier patients who could afford full price themselves.

China's 2016 NRDL reform, affecting over a billion people, did close to the opposite. It combined centralized government price negotiation with insurance expansion that also brought higher-income households into the covered pool, rather than restricting coverage to a narrower, cheaper group of only the poorest patients.

The reform paired two mechanisms that only work together: government negotiators centrally set prices for innovative drugs across the whole national market, while expanded insurance coverage -- including for wealthier households who could otherwise pay full price -- built a larger, more committed pool of buyers into the negotiation.

Paired centralized price negotiation with expanded insurance including the wealthy, whose price-insensitivity gave bargaining power, so the poor got lower prices too.

A small, guaranteed pool of only poor patients gives drugmakers no incentive to cut prices, since they lose little by refusing.

Including wealthier, less price-sensitive households makes the buyer pool larger and more attractive, so suppliers have real gains from trade to protect.

Centralized negotiation without a large pool gives firms no reason to discount, while insurance expansion without negotiation lets firms raise prices.

The combined reform produced an 18-point market share gain, exceeding the sum of insurance alone (5 points) and negotiation alone (0 points).

When negotiating with a concentrated supplier, deliberately expand your buying pool—even with price-insensitive members—to gain leverage that lowers prices for everyone.

Economists Panle Jia Barwick, Ashley Swanson and Tianli Xia, analyzing SinoHealth sales data from 2017-2023 focused on cancer drugs, found the reform reduced retail prices by 48% for successfully negotiated drugs (a later NBER Digest summary of a revised draft reported 57%) while 25-36% of negotiations failed outright; out-of-pocket costs for successfully negotiated drugs fell 80-89%, drug utilization rose 350%.